In September, the fertility start-up Kindbody gathered its doctors at a weekend retreat in a Los Angeles hotel. They bonded over morning yoga and swapped best practices for helping women conceive babies.
However, an announcement by Kindbody executives cast a pall over the event. The company was burning through cash. If it was going to turn a profit and go public, the 32 reproductive endocrinologists would need to raise the number of monthly egg retrieval attempts they perform by 12, said physicians who received performance plans reviewed by Bloomberg.
For some, this meant doubling procedures.
Photo: AP
At the retreat and in the days following it, several physicians pushed back vocally, calling the targets unreasonable and warning they could incentivize physicians to encourage intrusive, expensive treatments to patients who do not necessarily need them, said people familiar with the talks, who asked not to be identified to discuss internal matters.
The week after the retreat, Kindbody presented a plan to its board of directors, including investors from Perceptive Advisors, RRE Ventures and JPMorgan Chase & Co’s healthcare venture arm. The report ranked all of its doctors only by the average number of egg retrieval attempts they were performing.
Those who fell beneath a benchmark average of 23 were labeled as falling “below expectations,” documents showed.
This target would be raised by 43 percent to 33 per month in a direct bid to bolster finances, the company said in the presentation.
Kindbody said in a statement that it had set individual targets for doctors at the retreat to help the company reach a goal of getting 4,500 people pregnant.
The company disputed that it sets “a blanket target” for retrievals, and said that doctors are assessed by more than just retrieval numbers.
They are also judged on patient satisfaction, feedback and the success of their treatments, it said.
“Our guiding metric is the patient experience,” the company said.
A spokesperson did not comment on why doctors were ranked solely based on retrievals in the board presentation.
In-vitro fertilization (IVF), which Kindbody offers at its 33 clinics alongside other fertility services such as egg freezing, can cost patients upward of US$13,800, not including medications. Egg retrieval involves an often emotionally and physically taxing regimen of blood tests, ultrasounds and hormone injections, with potential side effects ranging from bloating to internal bleeding.
It is also the most lucrative procedure Kindbody offers, comprising about half of the revenue collected from an IVF cycle, said current and former Kindbody doctors, speaking on condition of anonymity as the information is not public.
Bundled packages are offered for US$27,000 and US$32,000, which cover two and three retrievals respectively.
IVF treatment in the US is also largely an out-of-pocket expense, with an estimated 56 percent of patients not covered by insurance, the resource and clinic review site FertilityIQ said.
Linking revenue to doctors’ productivity highlights an ongoing debate among academics and medical experts over the ethics behind for-profit companies in the business of reproductive health.
Kindbody — which has raised more than US$300 million from companies including Alphabet Inc and gained the backing of celebrities such as Gwyneth Paltrow — has directly connected the push for retrievals to its efforts to take the company public, according to six current and former Kindbody doctors, as well as documents reviewed by Bloomberg.
It is common practice for fertility clinics to measure their success by the number of babies born from IVF treatments. They are required by law to report live birthrates. While other fertility services providers track egg retrievals, one Kindbody rival says it does not set targets.
Kindbody said that the practice of tying monthly egg retrieval targets to doctors’ compensation and revenue forecasts is an industry standard, and it views egg retrievals as “a critical point of success” in the company’s efforts to increase access to fertility treatments.
“It is inaccurate and irresponsible to reduce fertility care — a highly technical, specific and individualized practice — to a single metric or portray it as driven solely by profit,” Kindbody said in its statement. “At Kindbody, patient care and maximizing the chances of patient success are paramount — not profit.”
At the same time Kindbody was giving its presentation to the board, multiple patients of one of the doctors ranked as falling below expectations received an e-mail saying that the physician would “transition out of” the clinic she directed, the time stamps on e-mails reviewed by Bloomberg showed.
Two other doctors Kindbody listed in the presentation as falling below the target have also since left the company, four current employees said.
The circumstances surrounding their departures are not clear. Kindbody said it hired four new doctors since September.
Perceptive and RRE, which have representatives on Kindbody’s board, did not respond to requests for comment on the presentation. Investor JP Morgan declined to comment.
“Having metrics is not a bad thing. The question is what determines those targets?” said Zev Williams, head of reproductive endocrinology and infertility at Columbia University Irving Medical Center.
“Patient needs, not profit calculations, should always come first,” he said.
Families might want to explore less invasive methods of becoming pregnant first, Williams said.
Not every fertility patient is seeking services that require an egg retrieval, he said.
China’s Huawei Technologies Co (華為) plans to start mass-producing its most advanced artificial intelligence (AI) chip in the first quarter of next year, even as it struggles to make enough chips due to US restrictions, two people familiar with the matter said. The telecoms conglomerate has sent samples of the Ascend 910C — its newest chip, meant to rival those made by US chipmaker Nvidia Corp — to some technology firms and started taking orders, the sources told Reuters. The 910C is being made by top Chinese contract chipmaker Semiconductor Manufacturing International Corp (SMIC, 中芯) on its N+2 process, but a lack
NVIDIA PLATFORM: Hon Hai’s Mexican facility is to begin production early next year and a Taiwan site is to enter production next month, Nvidia wrote on its blog Hon Hai Precision Industry Co (鴻海精密), the world’s biggest electronics manufacturer, yesterday said it is expanding production capacity of artificial intelligence (AI) servers based on Nvidia Corp’s Blackwell chips in Taiwan, the US and Mexico to cope with rising demand. Hon Hai’s new AI-enabled factories are to use Nvidia’s Omnivores platform to create 3D digital twins to plan and simulate automated production lines at a factory in Hsinchu, the company said in a statement. Nvidia’s Omnivores platform is for developing industrial AI simulation applications and helps bring facilities online faster. Hon Hai’s Mexican facility is to begin production early next year and the
Who would not want a social media audience that grows without new content? During the three years she paused production of her short do-it-yourself (DIY) farmer’s lifestyle videos, Chinese vlogger Li Ziqi (李子柒), 34, has seen her YouTube subscribers increase to 20.2 million from about 14 million. While YouTube is banned in China, her fan base there — although not the size of YouTube’s MrBeast, who has 330 million subscribers — is close to 100 million across the country’s social media platforms Douyin (抖音), Sina Weibo (新浪微博) and Xiaohongshu (小紅書). When Li finally released new videos last week — ending what has
TECH BOOST: New TSMC wafer fabs in Arizona are to dramatically improve US advanced chip production, a report by market research firm TrendForce said With Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) pouring large funds into Arizona, the US is expected to see an improvement in its status to become the second-largest maker of advanced semiconductors in 2027, Taipei-based market researcher TrendForce Corp (集邦科技) said in a report last week. TrendForce estimates the US would account for a 21 percent share in the global advanced integrated circuit (IC) production market by 2027, sharply up from the current 9 percent, as TSMC is investing US$65 billion to build three wafer fabs in Arizona, the report said. TrendForce defined the advanced chipmaking processes as the 7-nanometer process or more